Mathew Varghese, MD
Allergy · North Bergen, NJNPI 1407884125
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by GSK at 45.1% of the total. Reporting peaked in 2022 at $760 and has fallen 98.0% since, to $15 in 2025. That places this record below the midpoint for allergy clinicians in NJ, where the typical reported total is $4,027.
Across 51 payments — averaging $56.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$502
- Regeneron Healthcare Solutions, Inc.$276
- Sanofi$210
- AbbVie$149
- Optinose US, Inc.$142
- plus $298 from 5 others
Across 16 payments — averaging $5746.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$90K
- Teva Pharmaceuticals USA, Inc.$2K
What the payments were for
- Food & beverage$2,82698%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 22 | $1,296 |
| AstraZeneca | 6 | $502 |
| Regeneron Healthcare Solutions, Inc. | 4 | $276 |
| Sanofi | 8 | $210 |
| AbbVie | 3 | $149 |
| Optinose US, Inc. | 3 | $142 |
| Genentech USA, Inc. | 1 | $138 |
| Amgen | 1 | $102 |
| Pfizer | 1 | $30 |
| Kaleo, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,873 in reported general payments places this provider in the 45th percentile of 35 allergy providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 31 | $83,782 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $56,832 |
| XhanceFluticasone Propionate | 13 | $8,133 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 63 | $6,310 |
| Epinephrine | 27 | $4,934 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,280 |
| RyaltrisOlopatadine Hcl/Mometasone | 11 | $2,713 |
| Azelastine Hcl | 119 | $2,342 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,725 |
| Fluticasone Propionate | 80 | $1,655 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,176 |
| Ammonium Lactate | 19 | $543 |
| Hydroxyzine Hcl | 32 | $264 |
| Montelukast Sodium | 15 | $213 |
| Levocetirizine Dihydrochloride | 11 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $1,296 | $60,11298 claims |
| Optinose US, Inc.Xhance | $142 | $8,13313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 35 allergy providers in New Jersey.
Other allergy in North Bergen
- John OppenheimerCedar Knolls$922K
- Jeffrey WeissRiverdale$532K
- Jay KashkinFair Lawn$436K
- Gregory TociMarlton$317K
- Eugene GattiMarlton$43K
- Howard DruceSomerville$37K
- Shashank ShethVoorhees$33K
- Donatella GraffinoCedar Knolls$15K
- Maria Lania-HowarthVoorhees$12K
- Jamie ZachariasSewell$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.